46687
document
Double-blind , placebo-controlled trial of risperidone plus topiramate in children with autistic disorder . BACKGROUND Autism is a complex neurodevelopmental disorder that forms part of a spectrum of related disorders referred to as Autism Spectrum Disorders . The present study assessed the effects of topiramate plus risperidone in the treatment of autistic disorder . METHOD Forty children between the ages of 4 and 12 years with a DSM IV clinical diagnosis of autism who were outpatients from a specialty clinic for children were recruited . The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder . Patients were randomly allocated to topiramate+risperidone ( Group A ) or placebo+risperidone ( Group B ) for an 8-week , double-blind , placebo-controlled study . The dose of risperidone was titrated up to 2 mg/day for children between 10 and 40 kg and 3 mg/day for children weighting above 40 kg . The dose of topiramate was titrated up to 200 mg/day depending on weight ( 100 mg/day for < 30 kg and 200 mg/day for > 30 kg ) . Patients were assessed at baseline and after 2 , 4 , 6 and 8 weeks after starting medication . Measure of outcome was the Aberrant Behavior Checklist-Community ( ABC-C ) Rating Scale . RESULTS Difference between the two protocols was significant as the group that received topiramate had a greater reduction in ABC-C subscale scores for irritability , stereotypic behavior and hyperactivity/noncompliance . CONCLUSION The results suggest that the combination of topiramate with risperidone may be superior to risperidone monotherapy for children with autistic disorder . However the results need to be further confirmed by a larger randomized controlled trial .
46688
Intervention_Pharmacological
risperidone plus topiramate
46689
Intervention_Pharmacological
topiramate plus risperidone
46690
Intervention_Pharmacological
topiramate+risperidone
46691
Intervention_Pharmacological
placebo+risperidone
46692
Intervention_Pharmacological
risperidone
46693
Intervention_Pharmacological
topiramate
46694
Intervention_Pharmacological
topiramate
46695
Intervention_Pharmacological
topiramate
46696
Outcome_Other
Aberrant Behavior Checklist-Community ( ABC-C ) Rating Scale
46697
Outcome_Other
reduction in ABC-C subscale scores for irritability
46698
Outcome_Physical
stereotypic behavior
46699
Outcome_Mental
hyperactivity/noncompliance
46700
Participant_Age
children
46701
Participant_Condition
autistic disorder
46702
Participant_Condition
autistic disorder
46703
Participant_Sample-size
Forty
46704
Participant_Age
ages of 4 and 12 years
46705
Participant_Condition
DSM IV clinical diagnosis of autism
46706
Participant_Condition
severely disruptive symptoms
46707
Participant_Condition
autistic disorder
46708
Participant_Age
children
46709
Participant_Condition
autistic disorder